On July 23, 2026 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported that it has entered into a standstill agreement (the "Agreement") with Streeterville Capital, LLC ("Streeterville") relating to the Company’s outstanding Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The Agreement became effective on July 16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common stock unless, on a given trading day, the common stock trades at a price at least 10% above the "Minimum Price" (as defined under Nasdaq Rule 5635) (the "Standstill") provided that the Standstill shall terminate immediately upon the occurrence of any breach of the Agreement or any Event of Default (as defined in the Certificate of Designation for the Series E Preferred Stock). The Agreement temporarily limits potential dilution from conversions of the Series E Preferred Stock while preserving the existing rights and obligations of both parties under the related transaction documents.

Upon expiration or termination of the Standstill, Streeterville may resume converting shares of the Series E Preferred Stock in accordance with the terms of the applicable transaction documents. Except as expressly provided in the Agreement, the Series E Preferred Stock and all related transaction documents remain in full force and effect.

Additional information regarding the Agreement will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

(Press release, 20/20 GeneSystems, JUL 23, 2026, View Source [SID1234669411])

On July 23, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, reported that it has requested a Type B (pre-IND application) meeting with the U.S. FDA to discuss the development and regulatory strategy for its investigational lead product candidate, HCW11-018b, a tetravalent T-cell engager ("TCE") constructed with the Company’s proprietary TRBC drug development platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HCW11-018b is intended to treat solid tumors and is administered by subcutaneous injection. In preclinical studies, it has shown the ability to target tissue factor-expressing cancer cells and activate CD3-positive effector T cells, while simultaneously reducing immunosuppression in the tumor microenvironment. Immunosuppression in the tumor microenvironment can limit effector T-cell infiltration and antitumor activity in solid tumors, particularly in gynecologic and pancreatic cancers.

TCEs have emerged as a potent therapeutic modality to treat cancer. First-generation TCEs represented a breakthrough in immunotherapy but they continue to face significant challenges, including antigen selection, limited efficacy in solid tumors, tolerability and safety concerns, and require a complex manufacturing process. Extensive preclinical studies of HCW11-018b –including assessments of in vitro and in vivo potency, antigen specificity, pharmacokinetics, toxicity in nonhuman primates, and its therapeutic window — suggest that it may be able to overcome the limitations of earlier-generation TCEs.

Currently, the U.S. FDA and other regulatory agencies have approved eight TCEs to be used to treat 12 indications. Even with a very limited number of approved indications, approved TCEs generate multi-billion-dollar annual sales. The level of interest for this area from major pharmaceutical companies remains strong over many years, as indicated by the large number of high-value partnerships formed with innovative biotechnology companies developing second-generation TCEs. These partnerships have likely been driven by TCE’s potential in both oncology and autoimmune diseases.

Dr. Hing C. Wong, the Company’s Founder and CEO, stated, "We are pleased to have reached this important milestone in the development of HCW11-018b and look forward to discussing our proposed clinical trial designs, nonclinical testing programs, and CMC data with the FDA. HCW11-018b exhibits remarkable anti-tumor activities with high tolerability in animal models. We discovered that it can penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities."

Dr. Wong continued, "We believe we have established a robust, streamlined, and cost-efficient manufacturing process capable of producing high-quality cGMP material to support HCW11-018b in clinical development and potential future commercialization. Our manufacturing process is based on high-producing recombinant CHO cell lines and a proprietary monoclonal antibody needed for the affinity purification process. The monoclonal antibody is currently being manufactured under GMP standards using a top-tier CDMO."

About HCW11-018b:

HCW11-108b is designed to treat a wide spectrum of solid tumors with enhanced anti-tumor activities and tolerability. HCW Biologics has identified HCW11-018b as the lead candidate in its Tetravalent T-Cell Engager Program, known as the "Big BiTE." The unique structure of the Big BiTE combines a tumor-associated tissue factor-targeting BiTE with IL-15 immune stimulation, in addition to a TGF-β trap to address immunosuppression in the tumor microenvironment. HCW11-018b was created using the Company’s proprietary TRBC drug development platform, without using the Fc fusion technology commonly found in bi-specific or tri-specific fusion molecules. In extensive preclinical studies, HCW11-018b demonstrated that it induces robust, sustained, antigen-specific tumor killing, enhances CD8⁺ T-cell activation, survival, and effector functions and promotes tumor infiltration into solid tumors. Further, HCW11-018b demonstrated in preclinical studies that it does not trigger cytokine release syndrome, a major concern of using BiTEs, when used in its therapeutic dose range.

(Press release, HCW Biologics, JUL 23, 2026, View Source [SID1234669410])

On July 23, 2026 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported that new data on IMNN-001, the Company’s DNA-based interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer, will be featured in a poster presentation at the inaugural AACR (Free AACR Whitepaper) Conference on Drug Discovery and Development (AACR D3), July 21-24, 2026 in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR D3 is a new conference from the American Association for Cancer Research (AACR) (Free AACR Whitepaper) designed to bring together scientists, clinicians, biopharma companies and investors around emerging technologies and novel approaches spanning the drug discovery and development continuum, rather than focusing solely on late-stage clinical results. IMUNON’s presentation introduces its TheraPlas platform technology alongside supporting translational and clinical data from its ovarian cancer program.

The standard-of-care treatment for newly diagnosed advanced ovarian cancer has not meaningfully changed in three decades. IMNN-001 is a proprietary novel DNA-based agent that produces therapeutic levels of interleukin-12 (IL-12), a multipotent anti-tumor cytokine, directly to the tumor site. Unlike systemic administration of recombinant IL-12, which is associated with supraphysiological, transient exposure, IMUNON’s approach is designed to achieve durable, physiologically relevant local IL-12 production intended to drive sustained anti-tumor immune activity. Administered weekly over a 6-month period, we believe this offers a highly favorable safety and efficacy profile and has the potential to substantially improve therapeutic outcomes.

"Being selected to present at the inaugural AACR (Free AACR Whitepaper) D3 meeting is an important recognition of IMUNON’s platform and our team’s work in ovarian cancer," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "The medical and scientific communities’ interest in our IMNN-001 program in advanced ovarian cancer has been remarkable. This visibility comes at a pivotal time as we advance our Phase 3 OVATION-3 trial, and we look forward to sharing our progress with this influential audience of drug developers and investors."

"We are very pleased to have been invited to present our innovative and transformative drug delivery platform, our novel translational data and the strong clinical efficacy demonstrated in our ongoing trials in ovarian cancer at this global conference," said Douglas V. Faller, M.D., Ph.D., Imunon’s chief medical officer. "The AACR (Free AACR Whitepaper) D3 meeting is the first of its kind, featuring cutting-edge science, novel technologies, and emerging frameworks that promise to revolutionize how cancer therapies are discovered, developed, and delivered. Imunon’s proven ability to safely harness, for the first time, the multipotent anti-tumor activity of IL-12 for the benefit of women with advanced ovarian cancer is being showcased as an example of the future of immune-oncology, establishing a new paradigm for immunotherapy."

Data being presented include findings from the randomized, controlled Phase 2 OVATION-2 study in advanced ovarian cancer, demonstrating that IMNN-001 is safe, achieves local delivery of IL-12, and induces anti-tumoral immune responses. The poster reports that IMNN-001 plus neoadjuvant/adjuvant chemotherapy was associated with a numerical increase in median overall survival of over 13 months compared to chemotherapy alone (40.5 vs. 27.6 months), to remain consistent with the abstract submission. As recently announced, final results from the trial increased to a 14.7 month increase in medial overall survival (45.1 vs. 30.4 months).

Translational analyses further showed that IMNN-001 enhanced favorable ratios of CD8+/Tregs and CD8+/CD4+ cells in patients’ tumors and tumor microenvironment, both of which have been previously reported to be associated with improved patient outcomes and are consistent with the clinical benefit observed in the trial. IMNN-001 was safe and well-tolerated, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm of OVATION-2.

These findings support the rapidly recruiting pivotal Phase 3 OVATION-3 trial, which is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer; and if successful, will provide an immediate basis for a BLA filing and approval.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas platform technology, IMNN-001 is an IL-12 DNA plasmid encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

(Press release, IMUNON, JUL 23, 2026, View Source [SID1234669409])

On July 23, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, reported that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, Changing Treatment Landscape in Bladder Cancer, at the BTIG Virtual Biotechnology Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

(Press release, Innate Pharma, JUL 23, 2026, View Source [SID1234669408])

On July 23, 2026 Novocure (NASDAQ: NVCR) reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This was our strongest quarter to date, with record net revenues and active patients on therapy," said Frank Leonard, CEO, Novocure. "We continue to launch our therapies in multiple markets allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability."

Financial updates for the quarter ended June 30, 2026:

Total net revenues for the quarter were $183.6 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by active patient growth globally.
The U.S., Germany, France and Japan contributed $103.0 million, $23.3 million, $21.3 million and $11.8 million, respectively, with other active markets contributing $18.2 million.
$2.8 million in net revenue recognized from one-time benefits in the U.S., Germany and France.
Net revenue from Optune Lua and Optune Pax in the quarter was $7.0 million.
Recognized revenue from Optune Lua in the quarter was $5.4 million. The U.S., Germany and Japan contributed $1.9 million, $1.7 million and $1.8 million, respectively.
Recognized revenue from Optune Pax in the quarter was $1.6 million.
Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $6.0 million.
Gross margin for the quarter was 78% compared to 74% in the prior year. Cost of revenues in the quarter benefitted from a one-time $4.9 million tariff refund.
Research, development and clinical study expenses for the quarter were $51.4 million, a decrease of 8% from the same period in 2025. This decrease was primarily driven by lower direct clinical trial expenses from completed trials.
Sales and marketing expenses for the quarter were $61.7 million, an increase of 8% compared to the same period in 2025. This increase was primarily driven by costs associated with the launch of Optune Pax in the U.S. and Optune Lua in Japan.
General and administrative expenses for the quarter were $39.9 million, a decrease of 9% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses.
Net loss for the quarter was $15.7 million with loss per share of $0.13.
Adjusted EBITDA* for the quarter was $10.8 million.
Cash, cash equivalents and short-term investments were $440.6 million as of June 30, 2026.
Operational updates for the quarter ended June 30, 2026:

As of June 30, 2026, there were 5,128 total active patients on TTFields therapy globally.
Optune Gio
As of June 30, 2026, there were 4,636 active patients on Optune Gio, an increase of 11% from the same period in 2025.
The U.S., Germany, France and Japan contributed 2,341; 637; 471 and 553 active patients, respectively, with 634 active patients contributed by other active markets.
Optune Lua
As of June 30, 2026, there were 207 active patients on Optune Lua, an increase of 51% from the same period in 2025.
The U.S., Germany, France and Japan contributed 99; 38; 1 and 64 active patients, respectively, with 5 active patients contributed by other active markets.
Optune Pax
418 prescriptions for Optune Pax were received in the quarter.
As of June 30, 2026, there were 285 active patients on Optune Pax in the U.S.
Quarterly updates and achievements:

June 2026
Optune Pax received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.
2026 financial guidance:

Novocure’s updated guidance for the full year 2026, as of July 23, 2026, is summarized below:

Total net revenue: $710 million – $725 million (previous: $690 million – $710 million)
Guidance includes collective net revenue contribution from Optune Lua and Optune Pax between $20 million – $30 million.
Adjusted EBITDA*: $0 million – $15 million (previous: $(15) million – $0 million)
This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, foreign exchange rates as of June 30, 2026 and consistent quarterly gross margin in the mid-70s percent.

Anticipated clinical and regulatory milestones:

Decision by the U.S. Food and Drug Administration on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from non-small cell lung cancer (Q4 2026).
Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma (Q4 2026).
Conference call details

Novocure will host a conference call and webcast to discuss second quarter 2026 financial results at 8:00 a.m. EDT today, Thursday, July 23, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

(Press release, NovoCure, JUL 23, 2026, View Source [SID1234669407])